Janus激酶抑制剂治疗免疫介导炎症性疾病致主要心血管不良事件的研究进展  

Research progress on risk of major adverse cardiovascular events associated with Janus kinase inhibitors in treatment of immune-mediated inflammatory diseases

作　　者：赵丹洁 边原[2] 尹琪楠 王易 唐鹏 韩丽珠 Zhao Danjie;Bian Yuan;Yin Qi'nan;Wang Yi;Tang Peng;Han Lizhu(Department of Pharmacy,the First People's Hospital of Shuangliu District of Chengdu,West China(Airport)Hospital of Sichuan University,Chengdu 610299,China;Department of Pharmacy(Personalized Drug Therapy Key Laboratory of Sichuan Province),Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital(Affiliated Hospital of University of Electronic Science and Technology of China),Chengdu 610072,China;Department of Pharmacy,the Fifth Hospital of Sichuan Province,Chengdu 610031,China;Department of TCM Pharmacy,Chengdu Integrated TCM and Western Medicine Hospital,Chengdu 610041,China)

机构地区：[1]成都市双流区第一人民医院(四川大学华西空港医院)药学部,成都610299 [2]四川省医学科学院·四川省人民医院(电子科技大学附属医院)药学部(个体化药物治疗四川省重点实验室),成都610072 [3]四川省第五人民医院药剂科,成都610031 [4]成都市中西医结合医院中药剂科,成都610041

出　　处：《药物不良反应杂志》2025年第1期44-49,共6页Adverse Drug Reactions Journal

基　　金：国家重点研发计划(2020YFC2005506);中华国际医学交流基金会2023临床药学科研基金(Z-2021-46-2101-2023);中国药学会医院药学科研专项(CPA-Z05-ZC-2023-002)。

摘　　要：Janus激酶抑制剂(JAKi)是一类通过抑制多种细胞因子的过度反应,治疗多种免疫介导炎症性疾病的细胞内小分子靶向药物。目前JAKi有较好的疗效,但存在导致主要心血管不良事件(MACE)的风险,且具体作用机制尚不明确。本文综述了JAKi的药理作用机制和分类及在我国已上市的JAKi(托法替布、巴瑞替尼、芦可替尼、乌帕替尼和阿布昔替尼)相关MACE的研究进展,分析了导致MACE的风险因素,包括患者年龄、合并心血管疾病及炎症性疾病,JAKi种类、剂型和疗程等,为临床合理使用JAKi以及更好地预防JAKi相关MACE提供参考。Janus kinase inhibitors(JAKi)are a kind of small molecule targeted drugs used to treat a variety of immune-mediated inflammatory diseases by inhibiting the excessive response of a variety of cytokines.Currently,JAKi has shown good clinical efficacy,but it also has risk of major adverse cardiovascular events(MACE).The specific mechanism of JAKi-caused MACE is still unclear.This paper reviews the pharmacological molecular mechanisms and classification of JAKi and the research progress of MACE related to the JAKi(tolvaptan,baricitinib,ruxolitinib,upadacitinib,and abrocitinib)that have been approved for marketing in China.The risk factors that lead to MACE,including age,combined cardiovascular disease and inflammatory diseases,types of JAKi,dosage forms,and treatment duration are analyzed,so as to provide reference for the clinical rational use of JAKi and better prevention of MACE related to JAKi.

关 键 词：Janus激酶抑制剂 免疫介导炎症性疾病 主要心血管不良事件 托法替布 巴瑞替尼 芦可替尼 乌帕替尼 阿布昔替尼 

分 类 号：R969.3[医药卫生—药理学]